Clinical Trials Logo

Ovary Cancer clinical trials

View clinical trials related to Ovary Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04532645 Active, not recruiting - Ovary Cancer Clinical Trials

Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK

OVAL-1
Start date: December 11, 2020
Phase:
Study type: Observational

This is a retrospective observational medical records review study of BRCA mutated advanced (FIGO stage III-IV) ovarian cancer patients who received first dose maintenance olaparib in 1L setting in France, Italy and the UK. Physicians who treated ovarian cancer patients with olaparib in 1L setting will be requested to recruit patients to have their clinical data abstracted from their clinical records in line with local laws

NCT ID: NCT04205227 Active, not recruiting - Cancer Clinical Trials

ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors

Start date: February 18, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

First-in Human study evaluating the safety, tolerability and efficacy of ENB003 in combination with Pembrolizumab in solid tumors. The study is separated into two parts. Part A is a 3+3 dose escalation to define the recommended RP2D; this part will include metastatic melanoma, platinum resistant ovarian cancer, and pancreatic cancer patients subjects, but other solid tumors will be allowed. Once the RP2D is selected, the study will be expanded into metastatic melanoma, platinum resistant ovarian cancer, and pancreatic cancer subjects. A small number of sarcoma subjects will be included, as exploratory.

NCT ID: NCT04000880 Active, not recruiting - Breast Cancer Clinical Trials

Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health

AMPLIFY
Start date: March 4, 2020
Phase: N/A
Study type: Interventional

This research study will test the efficacy of interactive, web-based interventions that improve diet, physical activity and weight management changes among early stage survivors of breast, prostate, colorectal, endometrial, renal, thyroid, and ovarian cancers, as well as multiple myeloma and non-Hodgkin Lymphoma. Overarching outcomes also include physical function and performance, muscle mass, quality of life, and health utilities.